FDA reviews weight's affect on emergency contraceptive efficacy

The FDA is considering the question of whether new labeling is needed to reflect research questioning the effectiveness of morning-after pills for women weighing 165 pounds or more. European health regulators ordered HRA Pharma, a French drugmaker, to change the label for its emergency contraceptive Norlevo. Similar drugs are marketed in the U.S. as Plan B One-Step and as generics.

View Full Article in:

Reuters · Wall Street Journal (tiered subscription model), The

Published in Brief: